Replimune to resubmit RP1 BLA for advanced melanoma; FDA agrees to prioritize review

Replimune Group, Inc.

Company will resubmit BLA in coming days after collaborative FDA dialogue aligns on path forward.
FDA will treat resubmission as urgent matter and prioritize review due to high unmet need.
Approximately 8,500 Americans with advanced melanoma die each year; half fail checkpoint inhibitor therapy.
BLA supported by IGNYTE trial data in patients who progressed on anti-PD-1 therapy.
CEO Sushil Patel expressed gratitude to FDA for commitment to supporting patients and innovation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.